(Q33589472)

28 July 2017

title

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? (English)

1 reference

28 July 2017

0 references

1

Dennis M Black

1 reference

28 July 2017

3

Ann V Schwartz

1 reference

28 July 2017

Douglas C Bauer

2

1 reference

28 July 2017

Steven R Cummings

series ordinal

4

1 reference

28 July 2017

Clifford J Rosen

series ordinal

5

1 reference

28 July 2017

language of work or name

English

0 references

publication date

9 May 2012

1 reference

The New England Journal of Medicine

28 July 2017

published in

1 reference

28 July 2017

volume

366

1 reference

28 July 2017

issue

22

1 reference

28 July 2017

page(s)

2051-2053

1 reference

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015798

PubMed Central

reference URL

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015798

PubMed Central

reference URL

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015798

PubMed Central

reference URL

31 October 2018

Identifiers

DOI

10.1056/NEJMP1202623

1 reference

28 July 2017

1 reference

28 July 2017

1 reference